Results 221 to 230 of about 4,527 (242)

Comparison of the Gastrointestinal Side Effects of Naproxen Formulated as Plain Tablets, Enteric-Coated Tablets, Or Enteric-Coated Granules in Capsules

Scandinavian Journal of Gastroenterology, 1989
We studied the gastrointestinal side effects of three formulations of naproxen in 18 healthy male volunteers. In a Latin-square design crossover study, the subjects received 500 mg naproxen twice daily for 7 days as plain tablets, enteric-coated tablets, or enteric-coated granules in capsules.
L, Aabakken, B A, Bjørnbeth, B, Hofstad, B, Olaussen, S, Larsen, M, Osnes   +5 more
openaire   +2 more sources

Compression of enteric-coated pellets to disintegrating tablets

International Journal of Pharmaceutics, 1996
Abstract Enteric-coated sucrose pellets containing a layer of bisacodyl beneath the coating were compressed into tablets on an instrumented single-punch machine using four different filler-binders for direct compression. Different copolymers based on polymethacrylates were applied as coatings.
Thomas E. Beckert, Klaus Lehmann, Peter C. Schmidt   +2 more
openaire   +1 more source

Enteric coated naproxen tablets.

European journal of rheumatology and inflammation, 1995
It is postulated that the gastroduodenal mucosal side effects of naproxen are partly based on topical toxicity. With enteric coated aspirin tablets as a model product, enteric coated naproxen formulations have been developed. The extent of absorption is the same for enteric coated and plain tablets.
openaire   +1 more source

Gastrointestinal symptoms associated with enteric-coated sulfasalazine (Azulfidine EN tablets)

Modern Rheumatology, 2002
Abstract To investigate both the incidence and the dosage used to treat gastrointestinal (GI) symptoms associated with enteric-coated sulfasalazine (Azulfidine EN, AZL) in patients with rheumatoid arthritis (RA), we studied the clinical history of 153 RA patients, and any available data on GI symptoms that might have been associated with AZL.
S, Okubo, K, Nakatani, K, Nishiya
openaire   +2 more sources

Tolerance of Didanosine as Enteric-Coated Capsules versus Buffered Tablets

AIDS Patient Care and STDs, 2004
329 E Didanosine (ddI) is a nucleoside analogue that competitively inhibits the HIV reverse transcriptase enzyme. The lability of the molecule in acid milieu reduces its bioavailability to 10% when administered orally.1 A first approach to overcome this limitation was the formulation of ddI as buffered tablets, so that the absorption of the drug was ...
Pablo, Barreiro, Arturo, Corbatón, Marina, Núñez, Juan, González-Lahoz, Vincent, Soriano   +4 more
openaire   +2 more sources

Absorption and Metabolism of Aspirin Administered in Enteric-Coated Tablets

JAMA: The Journal of the American Medical Association, 1965
Variations in the absorption pattern of aspirin in enteric-coated tablets and in solution were compared between subjects and between doses in any one subject. Absorption of enteric-coated tablets was complete but the rate was extremely variable. On the other hand, administration of aspirin in solution was not only complete, but also yielded well ...
J R, LEONARDS, G, LEVY
openaire   +2 more sources

ENTERIC-COATED TABLETS

The Lancet, 1961
Arnold Bloom, A.J. Bowdler, R.E. Nagle
openaire   +1 more source

Disintegration Test for Enteric-Coated Tablets

Journal of Pharmaceutical Sciences, 1977
P L, Madan, H, Eisen
openaire   +2 more sources

Interaction of omeprazole with enteric-coated salicylate tablets.

International journal of clinical pharmacology and therapeutics, 1999
Enteric-coated tablets are designed to resist gastric fluids and to disrupt and dissolve in the alkaline medium of the small intestine. Main objective of the present study was to investigate whether the increase in gastric pH due to omeprazole treatment alters the release rate of a drug from enteric-coated formulation. To this end, we have compared the
F Z, Nefesoglu, G, Ayanoglu-Dülger, N B, Ulusoy, N, Imeryüz   +3 more
openaire   +1 more source

Aspirin dosing using 15 grain enteric coated tablets.

The Journal of rheumatology, 1985
A high unit dose (15 grain/975 mg) enteric coated aspirin preparation was studied in normal individuals and patients with arthritis to determine how readily well tolerated, therapeutic (150-300 micrograms/ml) salicylate (SA) levels could be achieved using a twice daily dosing regimen.
S, Pollet, R H, White, H, Jang, C W, Yim, D, Feigal   +4 more
openaire   +1 more source